Neurocrine Biosciences (NBIX)
(Delayed Data from NSDQ)
$146.50 USD
-0.62 (-0.42%)
Updated Jul 11, 2024 04:00 PM ET
After-Market: $146.42 -0.08 (-0.05%) 7:58 PM ET
1-Strong Buy of 5 1
D Value C Growth D Momentum D VGM
Income Statements
Fiscal Year end for Neurocrine Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 1,887 | 1,489 | 1,134 | 1,046 | 788 |
Cost Of Goods | 40 | 23 | 14 | 10 | 7 |
Gross Profit | 1,847 | 1,466 | 1,119 | 1,036 | 781 |
Selling & Adminstrative & Depr. & Amort Expenses | 1,597 | 1,217 | 1,017 | 873 | 708 |
Income After Depreciation & Amortization | 251 | 249 | 103 | 163 | 72 |
Non-Operating Income | 86 | -28 | 25 | -24 | 6 |
Interest Expense | 5 | 7 | 26 | 33 | 32 |
Pretax Income | 332 | 214 | 101 | 107 | 47 |
Income Taxes | 82 | 59 | 12 | -301 | 10 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 250 | 155 | 90 | 407 | 37 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 250 | 155 | 90 | 407 | 37 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | 255 | 266 | 131 | 193 | 98 |
Depreciation & Amortization (Cash Flow) | 4 | 17 | 28 | 30 | 26 |
Income After Depreciation & Amortization | 251 | 249 | 103 | 163 | 72 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 101.00 | 98.90 | 97.90 | 97.80 | 95.70 |
Diluted EPS Before Non-Recurring Items | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Diluted Net EPS (GAAP) | 2.47 | 1.56 | 0.92 | 4.16 | 0.39 |
Fiscal Year end for Neurocrine Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 515.30 | 515.20 | 498.80 | 452.70 |
Cost Of Goods | NA | 7.50 | 8.50 | 11.20 | 11.50 |
Gross Profit | NA | 507.80 | 506.70 | 487.60 | 441.20 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 408.50 | 356.40 | 346.40 | 367.60 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | 99.30 | 150.30 | 141.20 | 73.60 |
Non-Operating Income | NA | -63.70 | 49.00 | -24.50 | 49.30 |
Interest Expense | NA | 1.10 | 1.10 | 1.10 | 1.30 |
Pretax Income | NA | 34.50 | 198.20 | 115.60 | 121.60 |
Income Taxes | NA | -8.90 | 50.50 | 32.50 | 26.10 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | 43.40 | 147.70 | 83.10 | 95.50 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | 43.40 | 147.70 | 83.10 | 95.50 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 103.60 | 102.30 | 101.10 | 100.20 |
Diluted EPS Before Non-Recurring Items | NA | 0.42 | 1.44 | 0.82 | 0.95 |
Diluted Net EPS (GAAP) | NA | 0.42 | 1.49 | 0.82 | 0.95 |